Tepotinib. Selective MET receptor tyrosine kinase inhibitor, Treatment of lung and liver cancers

Medova, Michaela (2016). Tepotinib. Selective MET receptor tyrosine kinase inhibitor, Treatment of lung and liver cancers. Drugs of the Future, 41(11), p. 659. Prous Science 10.1358/dof.2016.041.11.2555984

Full text not available from this repository. (Request a copy)

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Medova, Michaela

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0377-8282

Publisher:

Prous Science

Language:

English

Submitter:

Beatrice Scheidegger

Date Deposited:

03 May 2017 15:24

Last Modified:

03 May 2017 15:24

Publisher DOI:

10.1358/dof.2016.041.11.2555984

URI:

https://boris.unibe.ch/id/eprint/94789

Actions (login required)

Edit item Edit item
Provide Feedback